Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Indaptus Therapeutics Inc (INDP)

Indaptus Therapeutics Inc (INDP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,066
  • Shares Outstanding, K 8,539
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,420 K
  • 60-Month Beta 1.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.70
Trade INDP with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.57
  • Number of Estimates 1
  • High Estimate -0.57
  • Low Estimate -0.57
  • Prior Year -0.51
  • Growth Rate Est. (year over year) -11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.03 +7.39%
on 03/28/24
2.95 -26.10%
on 04/15/24
-0.30 (-12.10%)
since 03/25/24
3-Month
1.56 +39.74%
on 02/13/24
2.95 -26.10%
on 04/15/24
+0.46 (+26.80%)
since 01/25/24
52-Week
1.56 +39.74%
on 02/13/24
4.08 -46.57%
on 09/19/23
-0.45 (-17.11%)
since 04/25/23

Most Recent Stories

More News
Indaptus (INDP) Surges on Upbeat Pre-Clinical Decoy Data

Indaptus (INDP) announces positive pre-clinical efficacy data from a poster presentation made at a scientific conference from its proprietary Decoy platform pre-clinical study. Stock is up 22%.

RCEL : 8.30 (-3.15%)
INDP : 2.18 (-7.23%)
BTTX : 0.0090 (+15.38%)
EQRX : 2.34 (-2.09%)
Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

U.S. Food and Drug Administration (FDA) Cleared Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of...

INDP : 2.18 (-7.23%)
Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A....

INDP : 2.18 (-7.23%)
Indaptus Therapeutics to Present at Jefferies Healthcare Conference

NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A....

INDP : 2.18 (-7.23%)
Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that the U.S. Food...

INDP : 2.18 (-7.23%)
Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference

NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”) today announced that Jeffrey A....

INDP : 2.18 (-7.23%)
Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of...

INDP : 2.18 (-7.23%)
Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update

NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces financial results...

INDP : 2.18 (-7.23%)
Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit

NEW YORK, March 17, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Michael J....

INDP : 2.18 (-7.23%)
Indaptus Therapeutics to Present at 34th Annual ROTH Conference

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey...

INDP : 2.18 (-7.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Indaptus Therapeutics approach is based on the hypothesis which efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals. Indaptus Therapeutics, formerly known as Intec...

See More

Key Turning Points

3rd Resistance Point 2.45
2nd Resistance Point 2.39
1st Resistance Point 2.28
Last Price 2.18
1st Support Level 2.11
2nd Support Level 2.05
3rd Support Level 1.94

See More

52-Week High 4.08
Fibonacci 61.8% 3.12
Fibonacci 50% 2.82
Fibonacci 38.2% 2.52
Last Price 2.18
52-Week Low 1.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar